NETHERLANDS - ABN AMRO Capital Life Sciences invests in Amsterdam Molecular Therapeutics

Wietske Blees
04 October 2006

Tweet
Facebook
LinkedIn
Google plus
Send to

ABN AMRO Capital Life Sciences (AAC LS) has announced that it has led a EUR 22m series-A financing of Amsterdam Molecular Therapeutics BV (AMT). The syndicate was completed by Advent Venture Partners, Gilde Investment Management and Crédit Agricole Private Equity. Sander Slootweg from ABN AMRO Capital Life Sciences has joined the company’s supervisory board.

Founded in 1998 on the initiative of researchers from the Academic Medical Center (AMC) in Amsterdam, AMT aspires to use its scientific know-how and expertise in the area of gene therapy in order to successfully develop innovative treatments for patients with serious inherited, metabolic or central nervous disorders.

The proceeds of this financing round will be used to take the clinical development of AMT’s lead product AMT-011, which is currently in phase II, through to registration. In addition, the funds will allow the company to accelerate its preclinical gene therapy programmes for two metabolic orphan diseases (acute intermittent porphyria and hyperoxaluria) addressing a significant unmet medical need, as well as a gene therapy to treat a rare and very serious and rapidly progressive retinal blindness.